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A B S T R A C T
Adjuvant bisphosphonates improve disease outcomes in postmenopausal early breast cancer (EBC) but the long-term effects are poorly described. The AZURE trial
(ISRCTN79831382) was designed to determine whether adjuvant zoledronic acid (ZOL) improves disease outcomes in EBC. Previous analyses showed no effect on
overall outcomes but identified benefits in postmenopausal women. Here we present the long-term risks and benefits of adjuvant ZOL with 10-years follow-up.
Patients and methods: 3360 patients with stage II/III breast cancer were included in an academic, international, phase III, randomized, open label trial. Patients were
followed up on a regular schedule until 10 years. Patients were randomized on a 1:1 basis to standard adjuvant systemic therapy+/− intravenous ZOL 4mg every
3–4 weeks x6, and then at reduced frequency to complete 5 years treatment. The primary outcome was disease free survival (DFS). Secondary outcomes included
invasive DFS (IDFS), overall survival (OS), sites of recurrence, skeletal morbidity and treatment outcomes according to primary tumor amplification of the tran-
scription factor, MAF. Pre-planned subgroup analyses focused on interactions between menopausal status and treatment effects.
Results: With a median follow up of 117 months [IQR 70.4–120.4), DFS and IDFS were similar in both arms (HRDFS= 0.94, 95%CI= 0.84–1.06, p=0.340;
HRIDFS= 0.91, 95%CI=0.82–1.02, p=0.116). However, outcomes remain improved with ZOL in postmenopausal women (HRDFS= 0.82, 95%CI= 0.67–1.00;
HRIDFS= 0.78, 95%CI=0.64–0.94). In the 79% of tested women with a MAF FISH negative tumor, ZOL improved IDFS (HRIDFS= 0.75, 95%CI= 0.58–0.97) and OS
HROS= 0.69, 95%CI= 0.50–0.94), irrespective of menopause. ZOL did not improve disease outcomes in MAF FISH+ tumors. Bone metastases as a first DFS
recurrence (BDFS) were reduced with ZOL (HRB-DFS= 0.76, 95%CI= 0.63–0.92, p=0.005). ZOL reduced skeletal morbidity with fewer fractures and skeletal events
after disease recurrence. 30 cases of osteonecrosis of the jaw in the ZOL arm (1.8%) have occurred.
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T
Conclusions: Disease benefits with adjuvant ZOL in postmenopausal early breast cancer persist at 10 years of follow-up. The biomarker MAF identified a patient
subgroup that derived benefit from ZOL irrespective of menopausal status.
Introduction
Despite improvements in both early diagnosis and treatment, breast
cancer remains the leading cause of cancer death in women in the de-
veloped world [1]. Late recurrence of the disease is frequent, especially
to bone, with disseminated malignant cells seemingly able to evade
adjuvant treatments and remain dormant, before re-activating and
causing disease relapse many years after diagnosis [2]. Therapeutic
strategies to improve disease outcomes include the use of bispho-
sphonates to affect the bone microenvironment [3].
The AZURE trial is an academic study, designed to test whether
treatment with the bisphosphonate, zoledronic acid (ZOL), could im-
prove disease outcomes in patients with stage II/III breast cancer.
Previous analyses after 752 [4] and 966 [5] disease free survival (DFS)
events showed that, despite a reduction in the risk of developing bone
metastases with ZOL, there was no effect on overall breast cancer re-
currence. However, preplanned subgroup analyses identified benefit in
women who were in established menopause at the time of study entry.
This observation was subsequently confirmed by the Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis of ad-
juvant bisphosphonates [6], resulting in recommendations both in
Europe [7] and North America [8] to consider use of adjuvant bi-
sphosphonates in postmenopausal women with early breast cancer.
Here, we present the 10 year follow-up results from the AZURE trial
and describe the effects of ZOL on disease relapse, skeletal morbidity,
site(s) of recurrence, overall survival and toxicity. We also explore the
interactive effects of menopausal status, age at diagnosis and the pre-
dictive biomarker MAF with ZOL on disease outcomes.
Methods
AZURE (BIG01/04) is an academic, prospective, randomized controlled
phase III, open label multi-national and multi-center trial
(ISRCTN79831382). The study design and patient eligibility have been
described previously [4,5], but, in summary, patients had histologically
confirmed invasive breast cancer of any biological subtype with either pa-
thologically confirmed axillary lymph node metastases or a T3/T4 primary
tumor. Patients were not eligible if there was clinical or imaging evidence of
distant metastases prior to study entry, current or recent (previous year) use
of bisphosphonates or pre-existing bone disease likely to require bone-tar-
geted treatment. All patients gave written informed consent.
Between September 2003 and February 2006, 3360 patients from 174
centers were randomized on a 1:1 basis using a central automated 24-
hour computer-generated telephone randomization system to receive
(neo)adjuvant systemic therapy with (ZOL) or without (CONTROL) zo-
ledronic acid. A minimization method was used to ensure balance in key
prognostic and treatment variables across the two groups [4].
ZOL 4mg was administered by intravenous (iv) infusion every 3–4
weeks for 6 doses, then 3 monthly x 8 and 6 monthly x 5 to complete 5
years treatment. Novartis Pharmaceuticals provided study-specific
supplies of ZOL. Daily oral supplements containing calcium
(400–1000mg) and vitamin D (200–500 IU) were recommended to all
trial subjects during the first six months, and continued thereafter at the
discretion of the treating physician.
Surgical management, the use and delivery of loco-regional external
beam radiotherapy, timing of adjuvant treatments in relation to surgery
and selection of chemotherapy and endocrine treatments were all
decided in accordance with standard protocols at each participating
institution. Trastuzumab was allowed in patients with HER2+ tumors
after regulatory approval for adjuvant use in 2006.
Table 1
Baseline patient characteristics.
Allocation
Standard treatment
alone
Standard
treatment+ZOL
Number Percent Number Percent
Lymph node involvement 32 1.9 30 1.8
• 0 nodes involved
• One–three nodes involved 1033 61.6 1042 62.0
• => four nodes involved 607 36.2 604 35.9
• Unknown involvement 6 0.4 5 0.3
Tumour stage 523 31.2 542 32.2
• T1
• T2 867 51.7 850 50.6
• T3 228 13.6 228 13.6
• T4 59 3.5 58 3.5
• TX 1 0.1 3 0.2
ER status 1315 78.4 1318 78.4
• ER positive
• ER negative 356 21.2 350 20.8
• ER unknown 7 0.4 13 0.8
PR status 699 41.7 725 43.1
• Positive
• Negative 424 25.3 382 22.7
• Unknown/missing 555 33.1 574 34.1
HER2 status 223 13.3 192 11.4
• Positive
• Negative 604 36.0 648 38.5
• Unknown/missing/not
measured
851 50.7 841 50.0
Histological grade 141 8.4 146 8.7
• 1
• 2 708 42.2 731 43.5
• 3 787 46.9 765 45.5
• Not specified/missing 42 2.5 39 2.3
Intended for neo-adjuvant
therapy
107 6.4 105 6.2
• Yes
• No 1571 93.6 1576 93.8
Intended systemic therapy
plan
76 4.5 76 4.5
• Endocrine therapy alone
• Chemotherapy alone 358 21.3 361 21.5
• Endocrine therapy and
chemotherapy
1244 74.1 1244 74.0
Intended use of
anthracyclines*
1564 93.2 1568 93.3
• Yes
• No 114 6.8 113 6.7
Intended use of taxanes* 385 22.9 390 23.2
• Yes
• No 1293 77.1 1291 76.8
Intended use of statins 100 6.0 97 5.8
• Yes
• No 1578 94.0 1584 94.2
Menopausal status 753 44.9 751 44.7
• Pre-menopausal
• Less than or equal to 5
years since menopause
243 14.5 247 14.7
• More than 5 years since
menopause
522 31.1 519 30.9
• Menstrual status
unknown
160 9.5 164 9.8
TOTAL 1678 100.0 1681 100.0
⁎ Patients intended to receive endocrine therapy alone are included as `no' to
the `anthracyclines' and `taxanes' questions
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Patients in both treatment arms were followed up on the same
schedule to fit in with administration of ZOL (where allocated) during
the first 5 years on trial. Thereafter, patients were reviewed annually
until 10 years. Follow-up investigations were as clinically indicated
with no protocol mandated imaging to identify sub-clinical metastatic
disease. Dates of recurrence were backdated to the first clinical suspi-
cion of relapse rather than the date confirmed.
The primary endpoint of the study was DFS, defined specifically for
Fig. 1. CONSORT diagram.
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this study as any recurrence of breast cancer (except for ipsilateral
operable invasive or in-situ relapse within a conserved breast) and
death from any cause without recurrence. Secondary endpoints in-
cluded invasive DFS (IDFS), defined according to STEEP guidelines [9];
time to bone metastasis at any time (TTBM) and as first DFS recurrence
(B-DFS); overall survival (OS); skeletal morbidity including fractures
before and after a DFS recurrence event, hypercalcaemia and skeletal
related events (SREs) associated with bone metastases (need for
radiotherapy, orthopaedic surgery and spinal cord compression). Pre-
specified subgroup analyses included menopausal status of the patient
prospectively defined at presentation and prior to randomization as
established (> 5years since menses), perimenopausal (within 5 years
of menses), premenopausal (regular menses) or unknown. Exploratory
analyses investigating treatment effects on site(s) of first recurrence,
breast cancer specific survival and relationships between patient age at
randomization and outcomes were also performed.
Following the discovery that amplification of the v-maf avian
musculoaponeurotic fibrosarcomaoncogene homolog (MAF) gene pre-
dicted for benefits and harms of adjuvant ZOL in an earlier analysis of
the AZURE trial [10], the long-term relationships between MAF am-
plification and treatment effects were evaluated. Primary tumor tissue
blocks were collected from 1769/2710 (65%) patients treated at par-
ticipating sites in the UK. Site participation in the collection of tumor
blocks was encouraged but not mandatory and, for logistical reasons,
restricted to UK sites. The MAF biomarker analysis was completed on
TMAs from these primary tumors.
All tumor blocks were sent to Sheffield for tissue microarray (TMA)
construction where the location of invasive tumor within the tissue
blocks was indicated by a single breast pathologist as a guide to the
technician extracting the tissue cores for construction of the TMAs.
Quadruplicate cores of 1mm in diameter of each of the tumor tissue
sample were arranged in 4 sets of 13 TMAs (150 samples each). All
analyses are restricted to study participants who gave specific patient
consent for the use of tissue samples.
The methodology for determining MAF status using a FISH based
assay has been described previously [10]. The MAF FISH test was
performed on primary tumors preserved in tissue microarray format by
an independent laboratory (Targos Molecular Pathology, Kassel, Ger-
many, blinded to patient details and treatment allocation. A pre-spe-
cified cut-off for MAF positivity of≥ 2.5 copies was defined prior to
any analysis. Prediction of treatment benefit was focused primarily on
IDFS, rather than the AZURE specific definition of DFS, and OS to en-
able future validation in other studies.
DFS, IDFS and OS were investigated using Kaplan–Meier survival
curves; time to bone metastases endpoints were calculated using cu-
mulative incidence functions (CIFs). Deaths without diagnosis of bone
metastases for TTBM and deaths without metastases and non-bone first
DFS recurrences for B-DFS were considered competing-risk events.
Differences between treatment arms were compared using the log-rank
test and Cox's proportional hazards model to adjust for minimization
factors (excluding center).
Osteonecrosis of the jaw (ONJ) rates were calculated using CIFs,
where deaths without diagnosis of ONJ were considered as competing-
risk events.
Subgroup analyses were performed using Cox's proportional hazards
model to adjust for statistically significant factors in the overall ana-
lyses for DFS, IDFS, B-DFS and OS (lymph node involvement and tumor
stage for all plus: ER status for DFS, IDFS and OS; menopausal status for
OS; neoadjuvant therapy for IDFS). Predictive analyses assessing the
interaction of MAF status with zoledronic acid were performed using a
Cox's proportional hazards model adjusted for minimization factors
previously shown to impact on prognosis (node status, grade, T stage).
Table 2
Recurrence events.
A – Disease free survival (DFS) as defined specifically for AZURE trial (see methods)
1st DFS event Standard treatment [n=1678] number
of events (%)
Standard treatment+ ZOL [n=1681] number
of events (%)
Total [n=3359] number of
events (%)
Loco-regional recurrence (excluding within
conserved breast)
106 (6.3%) 110 (6.5%) 216 (6.4%)
Distant recurrence* 431 (25.7%) 403 (24.0%) 834 (24.8%)
• Bone 244 (14.5%) 188 (11.2%) 432 (12.9%)
• Bone marrow 2 0 2
• Viscera 272 286 558
• CNS 35 36 71
• Soft tissue and other 53 59 112
Death without recurrence 63 (3.8%) 62 (3.7%) 125 (3.7%)
Total DFS events 575 (34.3%) 555 (33.0%) 1130 (33.6%)
B - Invasive disease free survival (IDFS) as defined by STEEP guidelines [9]
1st IDFS event Standard treatment [n=1678] number of
patients with event (%)
Standard treatment+ ZOL [n=1681] number of
patients with event (%)
Total (n=3359) number of patients
with event (%)
Loco-regional recurrence 127 (7.6%) 136 (8.1%) 263 (7.8%)
Distant recurrence 405 (24.1%) 378 (22.5%) 783 (23.3%)
Contralateral breast cancer 35 (2.1%) 22 (1.3%) 57 (1.7%)
Second non -breast
Malignancy
73 (4.4%) 59 (3.5%) 132 (3.9%)
Death without recurrence 36 (2.1%) 38 (2.3%) 74 (2.2%)
Total IDFS events 644 (38.4%) 606 (36.0%) 1250 (37.2%)
The distant recurrence categories are not mutually exclusive hence the numbers (and percentages where presented) in each category do not equal the total number of
patients with distant recurrences (as patients’ first DFS event). If a patient has more than one site of ‘viscera’ or ‘soft tissue and other’ distant recurrence reported on
the same day as their 1st DFS event, all sites will be reported and the patient will appear more than once for each distant recurrence; percentages are therefore not
presented for these categories.
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The assumption of proportional hazards for each treatment arm was
assessed by plotting the hazards over time (i.e. the log cumulative ha-
zard plot from SAS's LIFETEST procedure). A piecewise hazards ap-
proach [11] was utilized to investigate the effect of ZOL in years 0–5
and 5–10 for IDFS in postmenopausal patients.
For the predictive MAF biomarker analyses, the response to zole-
dronic acid treatment was tested comparing control and ZOL groups. A
predictive analysis, assessing the interaction of MAF status with
Fig. 2. Disease free (DFS) and invasive disease free survival (IDFS) by treatment allocation (Top panels - ITT analysis; Bottom panels - women who were in
established menopause (> 5 years since last menses) at study entry).
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treatment allocation, was performed using a Cox proportional hazards
model. Only minimization factors identified as statistically significant
in the prognostic analysis were included in the model to reduce po-
tential overfitting. In addition, predictive analyses were carried out for
patients who were unequivocally post-menopausal (> 5 years since
last menses) at trial entry separately to patients who were not post-
menopausal (pre-menopausal,≤ 5 years since menopause and meno-
pausal status unknown), given the significant heterogeneity of treat-
ment effect between established post-menopausal patients and all other
patients observed in the AZURE trial as a whole. The SAP for these
biomarker tests was defined before any data analysis was performed
with interactions between MAF+ve and effects of ZOL on disease
outcomes by menopausal status pre-specified.
All analyses presented are adjusted analyses. Hazard ratios with
95% confidence intervals (CI) are presented. Hypothesis testing was
two-sided with significance at 5%. No adjustments were made for
multiplicity. P values are restricted to the ITT analyses (main study and
biomarker subset) and, due to previous analyses [4,5] should be con-
sidered descriptive rather than inferential. Analyses were carried out in
SAS version 9.4 (SAS Institute Inc., Cary, NC).
Results
Baseline patient demographics, disease characteristics and systemic
anticancer treatments were balanced across the two randomized study
groups (Table 1). 3207 patients (95%) received chemotherapy (207
Fig. 3. Cumulative incidence of bone metastases as first DFS recurrence.
Table 3
Number of patients with each site of bone recurrence (as their first DFS recurrence).
Standard treatment alone [n=1678] number
of patients with event (%)
Standard treatment+ ZOL [n=1681] number of
patients with event (%)
Total [n=3359] number of patients
with event (%)
Site(s) of bone recurrence (as their first DFS recurrence)*
Hip (femur) 44 (2.6%) 25 (1.5%) 69 (2.1%)
Pelvis (not neck of femur) 60 (3.6%) 49 (2.9%) 109 (3.2%)
Spine (lumbar, thoracic,
cervical, coccyx)
153 (9.1%) 119 (7.1%) 272 (8.1%)
Leg (below knee) 1 (0.1%) 1 (0.1%) 2 (0.1%)
Arm 21 (1.3%) 7 (0.4%) 28 (0.8%)
Rib 52 (3.1%) 48 (2.9%) 100 (3.0%)
Scapula 14 (0.8%) 9 (0.5%) 23 (0.7%)
Sternum 27 (1.6%) 20 (1.2%) 47 (1.4%)
Clavicle 3 (0.2%) 4 (0.2%) 7 (0.2%)
Skull and facial bones 30 (1.8%) 15 (0.9%) 45 (1.3%)
Mandible 0 (0%) 2 (0.1%) 2 (0.1%)
Others 16 (1.0%) 16 (1.0%) 32 (1.0%)
Bone marrow – no focal bone
lesion
2 (0.1%) 6 (0.4%) 8 (0.2%)
Unknown 2 (0.1%) 2 (0.1%) 4 (0.1%)
Total 244 (14.5%) 188 (11.2%) 432 (12.9%)
⁎ The categories of sites of bone recurrences are not mutually exclusive hence the numbers (and percentages) in each category do not equal the total number of
patients with bone recurrences. If a patient has more than one site of bone recurrence reported on the same day as their first recurrence, all of the sites will be
reported and the patient will appear more than once in the corresponding column
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neoadjuvant chemotherapy), 2488 patients both chemotherapy and
endocrine treatment(s) and 152 patients endocrine treatment(s) alone
(CONSORT DIAGRAM, Fig. 1).
With a median follow up of 117 months (interquartile range (IQR)
70.4–120.4 months) at the data-lock on 7th June 2016, there have been
1130 DFS, 1250 IDFS, 910 OS events and 781 breast cancer deaths
[Table 2]. Follow-up was almost identical for ZOL (median 118, IQR
71.4–120.5 months) and CONTROL patients (median 116.3, IQR
69.2–120.4 months). Four ZOL patients were not evaluable for DFS or
IDFS (3 metastatic disease at randomization, one neoadjuvant patient
not proceeding to definitive surgery) and one CONTROL patient was
not evaluable for IDFS (another primary tumor at randomization); all
were censored at time zero in the relevant analysis.
The number of DFS (ZOL=555, CONTROL=575) and IDFS
(ZOL=606, CONTROL=644) events were similar in both arms
(HRDFS= 0.94, 95%CI:0.84–1.06, P=0.340; HRIDFS= 0.91,
95%CI:0.82–1.02, P=0.116) [Fig. 2A and B]. As with earlier analyses
[4,5], ZOL improved DFS and IDFS in patients who were > 5years
postmenopausal (ZOL=177, CONTROL=206 DFS events) at the time
of randomization (HRDFS= 0.82, 95%CI:0.67–1.00; HRIDFS= 0.78,
95%CI:0.64–0.94) [Fig. 2C and D]. The absolute difference in IDFS at
10 years was 7.8% (95%CI:1.4% to 14.2% [ZOL=59.9%, CON-
TROL=52.1%]). The benefits from treatment appear in the first five
years (during treatment) following which the IDFS curves run parallel.
The HRs were 0.68 (95%CI:0.53–0.87, P=0.002) and 0.89
(95%CI:0.65–1.21, P=0.456) in years 0–5 and 5–10 respectively. The
absolute difference in IDFS between treatments averaged from five
years onwards is consistent at about 6.5%.
Women who were not post-menopausal at study entry did not gain
benefit for either DFS (ZOL=378, CONTROL=369 events;
HRDFS= 1.03, 95%CI:0.89–1.19) or IDFS (ZOL=413,
CONTROL=411 events; HRIDFS= 1.01, 95%CI:0.88–1.16). The test
for interaction (TFI) by menopause on DFS was of borderline sig-
nificance (Chi2= 3.25, P=0.07).
Bone metastases as a first DFS recurrence (B-DFS) were reduced
with ZOL (ZOL=188, CONTROL=244 events; HRB-DFS= 0.76,
95%CI:0.63–0.92, P=0.005) (Fig. 3). The absolute difference in B-DFS
at 10 years was 3.6% (95%CI:1.1% to 6.0% [ZOL=11.9%, CON-
TROL=15.5%]). Treatment effects on this endpoint were similar in
postmenopausal (HRB-DFS= 0.76, 95%CI:0.53–1.07) and non-post-
menopausal women (HRB-DFS= 0.77, 95%CI:0.61–0.96); TFIB-DFS by
menopause Chi2= 0.005, P=0.94. Specific sites of bone metastases as
first DFS recurrence by treatment allocation are shown in Table 3.
Extra-skeletal distant recurrence DFS (E-dDFS) events (ZOL= 279,
CONTROL=264) were similar in the two treatment groups. However
heterogeneity of treatment effects on E-dDFS by menopause was seen.
In postmenopausal women the HR for E-dDFS was 0.77
(95%CI:0.57–1.04), whereas it was 1.22 (95%CI:0.99–1.50) in non-
postmenopausal women (TFI Chi2= 6.11, P=0.01).
Overall survival was similar in the two arms in the ITT analysis
(HROS=0.92 95%CI:0.81–1.05, P=0.24) [Fig. 4A]. However in the
postmenopausal cohort, improvements in OS (HROS=0.84,
95%CI:0.67–1.04) [Fig. 4B] and breast cancer mortality (HR=0.80,
95%CI:0.62–1.03) that approached statistical significance were seen.
The absolute difference in OS at 10 years was 4.4% (95%CI:−1.5% to
10.4% [ZOL=69.0%, CONTROL=64.6%]).
The MAF FISH test was assessable in 865 (26% of the entire AZURE
cohort) patients. These patients had similar tumor and treatment
characteristics (Table 4) and 10-year IDFS and OS outcomes to the
entire AZURE cohort. Six hundred and eighty (79%) were MAF negative
with≤ 2.5 copies per cell (ZOL 321, CONTROL 359). ZOL significantly
improved 10 year IDFS (HRIDFS= 0.75, 95%CI:0.58–0.97, P=0.026),
Fig. 4. Overall survival in the ITT analysis (A: left) and > 5years postmenopausal subgroup (B: right).
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bone IDFS (HRBDFS= 0.65, 95%CI:0.45–0.94, P=0.022) and OS
(HROS=0.69, 95%CI:0.50–0.94, P=0.019) in women with MAF ne-
gative tumors, irrespective of menopause (Fig. 5). On the other hand,
women with MAF positive tumors did not benefit from ZOL
(HRIDFS= 1.54, 95%CI:0.96–2.47, P=0.074) and OS (HROS= 1.40,
95%CI:0.83–2.33, P=0.204). Indeed, non-postmenopausal women
with MAF positive tumors had much worse outcomes (HRIDFS= 2.31,
95%CI:1.18–4.52, P=0.015; HROS= 2.28, 95%CI:1.07–4.82,
P=0.032) driven largely by an increase in extra-skeletal recurrences in
this patient sub-group (HRE-DFS= 4.57, 95%CI:1.66–12.57, P=0.003).
Exploratory analyses of study treatment effects on DFS by age
identified significant heterogeneity (Chi2(trend)= 7.70, P=0.0055).
Patients who were < age 40 at diagnosis had a worse outcome with
zoledronic acid (HRDFS= 1.69; 95%CI:1.24–2.29) [Fig. 6A]. This was
due in part to more B-DFS events (HRB-DFS= 1.59; 95%CI:1.01–2.49)
[Fig. 6B] but mainly reflected the markedly higher rates of DFS events
outside bone (E-DFS) (HRE-DFS= 2.06; 95%CI:1.43–2.97) in these
young women treated with ZOL [Fig. 6C]. The increase in relapse as-
sociated with zoledronic acid treatment in women aged < 40 was as-
sociated also with worse survival outcomes (HROS=1.56,
95%CI:1.09–2.22) at 10 years (Fig. 7).
Treatment with ZOL reduced skeletal morbidity. 470 SREs occurred
in 284/1681 (16.9%) of patients on ZOL compared with 700 SREs in
378/1678 (22.5%) of CONTROL patients (Table 5). Unlike in our ear-
lier report on fractures [12], ZOL now not only reduced fracture in-
cidence after a recurrence event (ZOL=52, CONTROL=79;
P= < 0.05) but also had an effect on fractures occurring in the ab-
sence of disease recurrence (ZOL=143, CONTROL=193;
P= < 0.05)).
Further follow up has not identified any new safety concerns since
the previous safety publication [13]. 30 confirmed cases of osteone-
crosis of the jaw (ONJ), all in the zoledronic acid arm, have occurred
(Fig. 8) with 4 occurring after a relapse in bone and use of a bispho-
sphonate in the metastatic setting and only 4 further cases have been
reported since the previous detailed analysis of ONJ reported earlier
[14]. The cumulative incidence of ONJ is 1.8% (95%CI:1.2%−2.5%).
There have been no reports of atypical femoral fracture.
Discussion
AZURE is one of the largest phase III studies of adjuvant bispho-
sphonates, and the first to report results with 10 years of follow-up. For
the entire ITT population, although zoledronic acid reduced bone me-
tastases as a first DFS recurrence, this did not translate into significant
effects on DFS, IDFS or OS. However, treatment benefits in women who
were in established menopause at the time of randomization persist out
to ten years with a clinically and statistically significant 6.5% absolute
IDFS benefit and a trend for improved breast cancer specific mortality.
Our findings remain consistent with those reported in the EBCTCG
meta-analysis [6].
In women who were not in established menopause at the time of
randomization, although there was a reduction in the risk of bone
metastases as a first DFS recurrence, this did not translate into benefits
in DFS, IDFS or OS. Indeed in the youngest patients included in this
study (aged < 40), zoledronic acid treatment was associated with an
increase in relapse, especially at extra-skeletal sites, and worse overall
survival, suggesting that inhibition of bone resorption in young women
may promote displacement and/or increase dissemination of viable
tumor cells to other organs.
MAF is a transcription factor of the AP-1 family encoded within 16q.
MAF regulates the expression of a set of genes that collectively support
several steps of breast cancer cell metastasis and progression [15]
epithelial-mesenchymal transition [16], macrophage function and a
number of interactions within the bone marrow niche including cell
adhesion [17]. Evaluation of the biomarker MAF using a FISH assay to
prospectively define MAF amplification appeared to identify the po-
pulation of women likely to benefit from adjuvant ZOL that avoids the
imprecise assessment of menopause and impacts of treatment on
ovarian function. The majority of women (79%) was deemed to be MAF
negative and, in this biomarker defined population, ZOL was associated
with relative risk reductions at 10 years of 35% for BDFS, 25% for IDFS
and 31% for OS irrespective of the postmenopausal status of the patient
at study entry. The predictive power of the MAF test has increased with
further follow-up since our original observations [10]. Women with a
MAF positive tumor do not benefit from ZOL and, in those who were
not postmenopausal at study entry, MAF positivity was associated with
a 4–5 fold risk increase in disease recurrence outside bone and worse
Table 4
Characteristics of MAF tested sub-set and overall AZURE trial population.
Variable FISH evaluable
result (n=865)
Tumour
provided
(n=1739)
AZURE
population
(n=3359)
Menopausal status
Non post-
menopausal
590 (68.2%) 1192 (68.5%) 2318 (69.0%)
Post-menopausal 275 (31.8%) 547 (31.5%) 1041 (31.0%)
Age
< 40 87 (10.1%) 198 (11.4%) 384 (11.4%)
40–49 299 (34.6%) 571 (32.8%) 1108 (33.0%)
50–59 281 (32.5%) 580 (33.4%) 1126 (33.5%)
60–69 162 (18.7%) 332 (19.1%) 628 (18.7%)
70+ 36 (4.2%) 58 (3.3%) 113 (3.4%)
Lymph node involvement
0 2 (0.2%) 17 (1.0%) 62 (1.8%)
1–3 563 (65.1%) 1122 (64.5%) 2075 (61.8%)
≥4 300 (34.7%) 598 (34.4%) 1211 (36.1%)
Unknown 0 (0%) 2 (0.1%) 11 (0.3%)
Tumour stage
T1 274 (31.7%) 577 (33.2%) 1065 (31.7%)
T2 475 (54.9%) 901 (51.8%) 1717 (51.1%)
T3 99 (11.4%) 214 (12.3%) 456 (13.6%)
T4 17 (2.0%) 47 (2.7%) 117 (3.5%)
TX 0 (0.0%) 0 (0.0%) 4 (0.1%)
ER status
ER positive 689 (79.7%) 1388 (79.8%) 2634 (78.4%)
ER negative 171 (19.8%) 341 (19.6%) 705 (21.0%)
ER unknown 5 (0.6%) 10 (0.6%) 20 (0.6%)
Systemic therapy plan
Endocrine therapy
(ET)
46 (5.3%) 89 (5.1%) 152 (4.5%)
Chemotherapy (CT) 166 (19.2%) 339 (19.5%) 719 (21.4%)
ET and CT 653 (75.5%) 1311 (75.4%) 2488 (74.1%)
Anthracyclines
Yes 794 (91.8%) 1604 (92.2%) 3132 (93.2%)
No 71 (8.2%) 135 (7.8%) 227 (6.8%)
Taxanes
Yes 126 (14.6%) 267 (15.4%) 775 (23.1%)
No 739 (85.4%) 1472 (84.6%) 2584 (76.9%)
HER2 status
Positive 93 (10.8%) 186 (10.7%) 415 (12.4%)
Negative 250 (28.9%) 503 (28.9%) 1251 (37.2%)
Unknown / Not
measured
522 (60.3%) 1050 (60.4%) 1693 (50.4%)
Histological grade
1 61 (7.1%) 147 (8.5%) 285 (8.5%)
2 333 (38.5%) 748 (43.0%) 1439 (42.8%)
3 467 (54.0%) 820 (47.2%) 1552 (46.2%)
Not specified 4 (0.5%) 24 (1.4%) 83 (2.5%)
PR status
Positive 308 (35.6%) 633 (36.4%) 1423 (42.4%)
Negative 159 (18.4%) 350 (20.1%) 806 (24.0%)
Unknown 398 (46.0%) 756 (43.5%) 1130 (33.6%)
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survival with ZOL use.
The mechanisms underpinning the inter-relationships between MAF
status and treatment effects are unclear. MAF over-expression appears
to influence trafficking of disseminated tumor cells away from the bone
microenvironment where bisphosphonates can influence the tumor and
stromal interactions, perhaps through additional inhibitory effects on
adhesion molecules and/or macrophage function, that may be influ-
enced by bisphosphonates, and encourage onward metastasis within
extra-skeletal sites. We are currently investigating the impact of MAF
status in preclinical models of bone metastasis and intend to try and
validate the predictive ability of MAF using the primary tumors and
trial data from the NSABP-B34 study of adjuvant oral clodronate. If our
findings in AZURE are confirmed, MAF could be used in the future to
select patients for adjuvant bisphosphonate treatment
Although adverse breast cancer mortality in young women was not
identified in the EBCTCG meta-analysis, there was significant hetero-
geneity of treatment effect in breast cancer mortality across age groups
(Chi2 for trend= 3.9, P=0.05) [6] and worse survival was reported in
one of the early clodronate trials that recruited a large proportion of
younger women [18]. Our results serve as a timely reminder that ma-
nipulating the host environment, either intentionally as a cancer
treatment strategy or as a bystander effect of other therapeutic inter-
ventions, has the potential to cause harm as well as good.
Of note, women aged 40–50, many of whom would likely have
experienced chemotherapy-induced amenorrhea (data not collected),
did not appear to gain benefit. Zoledronic acid was administered for
five years and, due to the very long retention of the drug in the skeleton
[19] with continuing effects on bone metabolism expected throughout
much if not all of the additional 5 years of follow-up, manipulation of
the bone environment did not appear to modify the late emergence of
tumor cells from the dormant state. The benefits observed from ad-
juvant bisphosphonates in postmenopausal women would seem to
argue for effects on early events in the metastatic process, perhaps in-
cluding seeding of tumor cells to osteoblastic and other cellular niches
in the bone marrow and/or an influence on tumor dormancy within a
postmenopausal bone micro-environment, rather than on later steps
such as emergence from dormancy and onward dissemination.
Adjuvant zoledronic acid was associated with a reduction in skeletal
morbidity with fewer fractures during follow-up and a reduction in
SREs related to metastatic bone disease. Improvements in the structural
integrity of bone achieved with ZOL appear to persist beyond treatment
cessation with a carry-over effect that reduces the morbidity associated
with metastatic disease even though most patients (data not shown)
received bone targeted treatment after a bone relapse.
Since the first report of the AZURE trial [4] and the suggestion that
the benefit of adjuvant bisphosphonates might be restricted to women
with low levels of reproductive hormones, as in ABCSG-12 [20] and the
pre-defined subgroup of women in AZURE with established menopause
(defined as > 5 years since last menses), there have been many attempts
to try and validate this hypothesis. NSABP B34 identified possible benefits
from adjuvant oral clodronate in women > 50 at time of randomization
[21] and the GAIN investigators suggested improved outcomes in older
women (aged > 60) with daily oral ibandronate [22].
The persistent benefits seen in AZURE at 10 years, with fewer bone
relapses and improved DFS and breast cancer mortality in post-
menopausal women, argue for inclusion of a bisphosphonate into ad-
juvant treatment programs from the outset. The lack of benefits in
women who will have become menopausal, either through ageing or
the effects of chemotherapy during the course of breast cancer treat-
ment, should discourage the use of delayed intervention of a bispho-
sphonate in the hope that this will also bring about benefits in terms of
breast cancer relapse. Such a strategy is worthy of appropriate clinical
trials but, currently, there is no evidence to support such an approach.
To address relationships between treatment benefit and menopausal
status more comprehensively, the EBCTCG conducted a meta-analysis
of > 18,000 women included in randomized trials of adjuvant bi-
sphosphonates with a specific aim to test the hypothesis that treatment
benefits were related to menopausal status of the patient at the time
bisphosphonates are initiated [6]. This individual patient meta-analysis
identified relative risk reductions in both the development of bone
metastases and death from breast cancer at 10 years of 28%
(P=0.0002) and 18% (P=0.002) respectively in postmenopausal
women but no suggestion of benefits in those who were premenopausal
at initiation of treatment, even though many of these would have be-
come postmenopausal during follow-up. Exclusion of the hypothesis
generating studies (ABCSG-12 and AZURE) did not materially change
Fig. 5. Invasive disease free (IDFS) and overall survival (OS) by treatment allocation in the 79% of patients tested who did not over-express (copy number < 2.5) the
MAF gene.
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the study findings.
These results have led to supportive clinical guidelines in Europe
and North America [7,8], a consensus recommendation by a European
expert group to incorporate adjuvant bisphosphonates into routine
clinical care [23] and adoption of these recommendations in some
health care systems. Despite the clinically important effects on breast
cancer mortality, global acceptance has been slow, in part due a lack of
regulatory approval for these generic medicines but also due to the
Fig. 6. Exploratory analyses investigating the impact of age at randomization on disease outcomes with or without adjuvant zoledronic acid: A:top – All DFS events;
B:middle – bone DFS events; C:bottom – all DFS other than bone events.
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finding that these benefits relate only to a subset of patients that is
somewhat imprecise in its definition and also because mechanistic ex-
planations for the findings remain unclear. The relationship between
MAF status in the primary tumor and treatment outcome, if confirmed,
may improve adherence to clinical guidelines.
There are some limitations to our study findings. Adjuvant systemic
treatments have evolved since AZURE started in 2003. Most notably,
the treatment of HER2+breast cancer with trastuzumab has been
standard treatment since 2006 and also the clear preference for the
routine use of aromatase inhibitors over tamoxifen for postmenopausal
ER+ breast cancer is well established with extended (> 5years) use in
some women. Less than half of the HER2 positive patients included in
AZURE received trastuzumab and only around two thirds of women
received an aromatase inhibitor, with most use being after a few years
of tamoxifen rather than as initial endocrine treatment. However, the
consistent benefits seen in the meta-analysis [6] within the post-
menopausal population, irrespective of clinic-pathologic (no differences
by histologic grade or nodal involvement) and biological subtypes (no
differences by ER status) suggest that these results remain valid.
Finally, if an adjuvant bisphosphonate is to be used, which agent
and schedule should be recommended? Both the meta-analysis and the
initial report of the SWOG-0307 study [24] suggest the benefits are
similar for zoledronic acid, daily oral clodronate and daily oral iban-
dronate. The AZURE and SWOG-0307 schedule of zoledronic acid is
intensive and associated with a small but not insignificant rate of ONJ.
In the absence of clear evidence of a dose response relationship, a less
Fig. 7. Exploratory analyses investigating the impact of age at randomization on overall survival (top) and breast cancer survival (bottom) with or without adjuvant
zoledronic acid.
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intensive regimen of zoledronic acid, as pioneered by the ABCSG [21],
or daily oral therapy with clodronate or ibandronate seem reasonable.
Interestingly the use of adjuvant denosumab in early breast cancer,
despite its ability to reduce the frequency of aromatase inhibitor asso-
ciated fractures [25], failed in the large randomized D-CARE
(NCT01077154) study to meet the primary objective of improving bone
metastases free survival. IDFS and OS were also similar and there was
no suggestion of a treatment interaction with menopausal status [26].
The lack of disease benefits from denosumab also suggest that inhibi-
tion of bone resorption is necessary but not sufficient to prevent me-
tastases. Bisphosphonates have multiple other cellular effects beyond
osteoclast inhibition including effects on tumor cell adhesion, angio-
genesis and immune function [27]. Further research is required to
understand whether some or all of these “off target” effects are
clinically relevant.
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